Akili, Inc. (AKLI)
Jul 2, 2024 - AKLI was delisted (reason: acquired by Virtual Therapeutics)
0.433
+0.001 (0.25%)
Last trade price
AKLI's stock price has decreased by -62.66% in the past year and price targets may not have had time to catch up.
Akili Analyst Ratings
Total Analysts
1
Consensus Rating
Buy
Price Target
$4.00
Upside
+823.57%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Credit Suisse | Credit Suisse | Buy Reiterates $4 | Buy | Reiterates | $4 | +823.57% | Aug 11, 2023 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $2 → $3 | Hold | Maintains | $2 → $3 | +592.68% | Jan 25, 2023 |
| Morgan Stanley | Morgan Stanley | Hold Initiates $2 | Hold | Initiates | $2 | +361.79% | Dec 28, 2022 |
| B of A Securities | B of A Securities | Hold Initiates $2 | Hold | Initiates | $2 | +361.79% | Nov 18, 2022 |
| Credit Suisse | Credit Suisse | Buy Maintains $4 → $4.5 | Buy | Maintains | $4 → $4.5 | +939.02% | Nov 15, 2022 |
| Credit Suisse | Credit Suisse | Buy Initiates $5 | Buy | Initiates | $5 | +1,054.47% | Oct 25, 2022 |
| Cowen & Co. | Cowen & Co. | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Sep 6, 2022 |